Raúl Insa

Raúl Insa

Auto-generated profile, based on publicly available information

Raúl Insa

SOM Innovation Biotech SA Barcelona Spain

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2019 in Amyloid
Verified
Journal Article
Closed access
JGJosep Gamez
Josep Gamez
MSMaría Salvadó
María Salvadó
NRNúria Reig
Núria Reig
PSPilar Suñé
Pilar Suñé
CCCarlos Casasnovas
Carlos Casasnovas
RIRaúl Insa
Raúl Insa
Objective: To assess the transthyretin (TTR) stabilization activity of tolcapone (SOM0226) in patients with hereditary ATTR amyloidosis, asymptomatic carriers and healthy volunteers. Methods: A phase IIa proof-of-concept trial included two phases separated by a 6-week washout period. Phase A: single 200 mg dose of tolcapone; phase B: three 100 mg doses taken at 4 h intervals. The primary efficacy variable was TTR stabilization. Results: Seventeen subjects were included (wild type, n = 6; mutation TTR Val30Met, n = 11). TTR stabilization was observed in all participants. Two hours after dosing, 82% of participants in phase A and 93% of those in phase B reached a TTR stabilization value of at least 20%. In phase A, there was an increase of 52% in TTR stabilization vs baseline values 2 h after dosing, which decreased to 22.9% at 8 h. In phase B, there was a significant increase of 38.8% in TTR stabilization 2 h after the first 100 mg dose. This difference was maintained after 10 h and decreased after 24 h. No serious adverse events were observed. Conclusions: The ability of tolcapone for stabilizing TTR supports further development and repositioning of the drug for the treatment of ATTR amyloidosis. EudraCT trial number: 2014-001586-27 ClinicalTrials.gov Identifier: NCT02191826

17 July 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Anna Nardi RicartAnna Nardi Ricart
Anna Nardi Ricart
INIsaac Nofrerias-Roig
Isaac Nofrerias-Roig
MSMarc Suñé-Pou
Marc Suñé-Pou
Pilar Pérez-LozanoPilar Pérez-Lozano
Pilar Pérez-Lozano
MMMontserrat Miñarro
Montserrat Miñarro
Josep Suñé-NegreJosep Suñé-Negre
Josep Suñé-Negre
Hydrophilic matrix tablets are a type of sustained release dosage form characterized by distributing a drug in a matrix that is usually polymeric. Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase. In recent years, it has been shown that tolcapone is a potent inhibitor of the amyloid aggregation process of the transthyretin protein, and acts by stabilizing the structure of the protein, reducing the progression of familial amyloid polyneuropathy. The main objective of this study was to obtain a sustained release tablet of tolcapone for oral administration with a preferred dosage regimen of 1 administration every 12 or 24 h and manufactured, preferably, by direct compression. The SeDeM Diagram method has been used for the formulation development of hydrophilic matrix tablets. Given the characteristics of tolcapone, the excipient selected for the formation of the polymeric matrix was a high viscosity hydroxypropylmethylcellulose (Methocel® K100M CR). A decrease in the particle size of tolcapone resulted in a slower dissolution release of the formulation when the concentration of the polymer Methocel® K100M CR was below 29%. These surprising and novel results have given rise to patent number WO/2018/019997.

28 December 2022 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
JGJosep Gamez
Josep Gamez
MCMatilde Calopa
Matilde Calopa
EMEsteban Muñoz
Esteban Muñoz
AFAileen Ferré
Aileen Ferré
OHOscar Huertas
Oscar Huertas
JKJaime Kulisevsky
Jaime Kulisevsky

29 January 2009 in Acta Neurologica Scandinavica
Verified
Journal Article
Open access
PDF file
Jorge Matias-GuiuJorge Matias-Guiu
Jorge Matias-Guiu
FBF. Bolumar
F. Bolumar
RMR. Martin
R. Martin
RIR. Insa
R. Insa
PCP. Casquero
P. Casquero
JAJ. Aranaz
J. Aranaz
Alcoy is a defined health region in eastern Spain, at 3 degrees E-38 degrees N, with a single neurology department and includes 33 towns with a total population of 133,915 inhabitants. We have evaluated the prevalence and incidence of multiple sclerosis (MS) by analysing this region. Six new cases have been detected (2.24/100,000/year) and the prevalence rate was 17.17/100,000, the highest in Spain at the moment. However, we found an irregular distribution in the different towns in so far that 15 of our 23 patients lived in a particular subregion, which means a prevalence of 44.59/100,000. Our study shows that the area of Alcoy is a medium MS risk region according to the thesis of Kurzke, although high MS areas may be found, thus confirming that MS distribution in southern Europe is not uniform.

Verified
Journal Article
Open access
PDF file
SJSeri Jo
Seri Jo
LSLuca Signorile
Luca Signorile
SKSuwon Kim
Suwon Kim
MKMi-Sun Kim
Mi-Sun Kim
OHOscar Huertas
Oscar Huertas
DSDong Hae Shin
Dong Hae Shin
The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) wreaked havoc all over the world. Although vaccines for the disease have recently become available and started to be administered to the population in various countries, there is still a strong and urgent need for treatments to cure COVID-19. One of the safest and fastest strategies is represented by drug repurposing (DRPx). In this study, thirty compounds with known safety profiles were identified from a chemical library of Phase II-and-up compounds through a combination of SOM Biotech’s Artificial Intelligence (AI) technology, SOMAIPRO, and in silico docking calculations with third-party software. The selected compounds were then tested in vitro for inhibitory activity against SARS-CoV-2 main protease (3CLpro or Mpro). Of the thirty compounds, three (cynarine, eravacycline, and prexasertib) displayed strong inhibitory activity against SARS-CoV-2 3CLpro. VeroE6 cells infected with SARS-CoV-2 were used to find the cell protection capability of each candidate. Among the three compounds, only eravacycline showed potential antiviral activities with no significant cytotoxicity. A further study is planned for pre-clinical trials.

5 April 2016 in Neurology
Verified
Journal Article
Closed access
JGJosep Gamez
Josep Gamez
NRNúria Reig
Núria Reig
Salvador VenturaSalvador Ventura
Salvador Ventura
MSMaria Maria Salvado
Maria Maria Salvado
RIRaul Insa
Raul Insa